<DOC>
	<DOCNO>NCT01953406</DOCNO>
	<brief_summary>The aim study evaluate efficacy 5-fluorouracil + Mitomycin patient pulmonary metastasis hepatocellular carcinoma progressive disease sorafenib .</brief_summary>
	<brief_title>The Efficacy 5-fluorouracil/Mitomycin Patients With Pulmonary Metastasis Hepatocellular Carcinoma</brief_title>
	<detailed_description>Extrahepatic metastasis hepatocellular carcinoma recently paradoxically increase due increase survival effective locoregional therapy . Sorafenib first systemic agent demonstrate significant survival benefit patient advance HCC ; however , modest improvement 3 month far satisfactory . There convince evidence , date , systemic chemotherapy tumor progress sorafenib therapy improve overall survival . The combination anticancer agent important achieve favourable clinical result . For patient metastatic liver cancer HCC , study discuss effectiveness 5-fluorouracil/mitomycin ( FM ) . However , study examine actual FM regimen HCC . The aim study evaluate efficacy 5-fluorouracil/mitomycin patient pulmonary metastasis hepatocellular carcinoma progressive disease sorafenib .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>Patients receive previous local therapy treatment intrahepatic hepatocellular carcinoma ( RFA , PEI , cryoablation , surgery , resection ) n't viable intrahepatic tumor within 3 month image ( dynamic liver CT liver MRI ) locoregional therapy Patients measurable lung metastasis Patients receive last dose sorafenib 14 day progressive disease lung metastasis sorafenib Patients risk factor hepatocellular carcinoma ( chronic hepatitis B , chronic hepatitis C , liver cirrhosis ) Age : 18 year 80 year ECOG Performance Status 0 2 ChildPugh class A , B ( ChildPugh score 59 ) Adequate bone marrow , liver function assess follow laboratory requirement conduct within 7 day prior screen : WBC count &gt; 1,000/mm3 Absolute neutrophil count &gt; 500/mm3 Hb &gt; 7.0 g/dL Platelet count &gt; 50,000 /mm3 Bilirubin &lt; 3 mg/dL Adequate clotting function : INR &lt; 2.3 &lt; 6sec ChildPugh score &gt; 10 ECOG Performance Status &gt; 3 History organ allograft Patients uncontrolled comorbidity need treatment Patients receive prior systemic chemotherapy except sorafenib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>5-fluorouracil/mitomycin</keyword>
</DOC>